Cholecystectomy surgery. Retained cholelithiasis following cholecystectomy
Conditions
Interventions
Intervention 1: Intervention group 1: Patients will receive Granisetron (Caspian Tamin Rasht Pharmaceutical Company – Iran) at a dose of 20 micrograms per kilogram and 1.25 mg of Droperidol (Panpharma
Sponsors
Vice chancellor for research, Arak University Of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients who are candidates for laparoscopic cholecystectomy ASA class I or II both of gender Having informed consent to participate in the study Patients with no history of renal, hepatic, or cardiovascular disease Absence of any history of drug abuse, alcohol use, or chronic analgesic consumption Absence of a history of malignancy No history of hypertension, diabetes, or hematologic/vascular disorders No history of psychiatric or psychotic disorders No history of Parkinson’s disease, movement disorders, or chemotherapy No known sensitivity to study medications and no seasonal allergies All patients undergoing general anesthesia Surgery performed by a surgeon Surgical duration ranging from 60 to 150 minutes
Exclusion criteria
Exclusion criteria: Lack of consent to continue participation in the study Possible death of the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of nausea. Timepoint: Recovery and 2, 4, 6, 12 and 24 hours after surgery. Method of measurement: Score 0 to 10.;Vomiting. Timepoint: Recovery and 2, 4, 6, 12 and 24 hours after surgery. Method of measurement: Score 0 to 4.;Sedation. Timepoint: Recovery and 2, 4, 6, 12 and 24 hours after surgery. Method of measurement: Ramsay score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Alireza Sosanabadi
Arak University of Medical Sciences
Outcome results
None listed